

Pediatric CIRB Meeting Agenda

October 12, 2023

I. Initial Review

ARAR2221, Phase 2 Study Using Chemoimmunotherapy with Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC) (Version Date 08/24/23)

II. Amendment

APEC14B1, The Project:Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study (Version Date 08/15/23)

III. Continuing Review

ACNS2021, A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (Version Date 11/17/21)

IV. Continuing Review

AGCT1531, A Phase 3 Study of Active Surveillance for Low risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors (Version Date 06/29/22)

V. Continuing Review

ANHL1931, A Randomized Phase 3 trial of Nivolumab(NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma (Version Date 08/07/23)

VI. Continuing Review

AOST2031, A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma (Version Date 12/06/22)
